ARTICLE | Product Development
How a KRAS program transformed Mirati's story
A look into the factors driving Mirati's stock moves as the market anticipates its first KRAS inhibitor data
October 26, 2019 2:15 AM UTC
With the first clinical data due on Mirati’s KRAS inhibitor next week, the market will get its first chance to justify -- or otherwise -- the large chunk of the company’s $3 billion valuation tied to the asset.
All eyes will be on how the Phase I/II KRAS G12C inhibitor MRTX849 from Mirati Therapeutics Inc. (NASDAQ:MRTX) measures up against AMG 510, an inhibitor from Amgen Inc. (NASDAQ:AMGN) against the same target. Amgen’s compound is just a few months ahead and has an impressive early data set...
BCIQ Target Profiles